BioSpace News Archive

Incyte (Nasdaq:INCY) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of ruxolitinib (Jakavi®) for the treatment of patients aged 12 years and older with acute graft-versus-host disease or chronic graft-versus-host disease (GVHD) and who have inadequate response to corticosteroids or other systemic therapies.

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX®.

Amgen (NASDAQ: AMGN) today announced that new Otezla (apremilast) data, along with findings on the unmet need for patients with plaque psoriasis, will be presented at the American Academy of Dermatology (AAD) congress in Boston, Massachusetts, March 25-29, 2022.

Encompass Health Corp. announced it will report results for its first quarter ended March 31, 2022, after the market closes on April 27, 2022.

First-in-Man Use of the Tractus ™ Crossing Support Catheter with its Jigsaw Technology ™ Shaft.

Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company will participate in a panel at the 2022 Virtual Growth Conference.

Xcelerate, Inc. recently announced that it signed a Membership Interest Purchase Agreement to acquire a 51% interest in AfiyaSasa Africa, LLC, a start-up medical technology and virtual health company, recently founded by Dr. Dilan Ellegala and Doyle Word.

Orphan drug are novel pharmaceutical drugs which have been developed specifically to treat rare medical conditions. Rare diseases are often severe and chronic, and sometimes progressive.

Many in vitro models simulate nonalcoholic steatohepatitis (NASH) conditions by culturing human hepatocytes in fatty acid-enriched media.

Rise in the incidence of actinic keratosis has given way to desirable use of up-to-date therapeutics, which in turn has led to a steep increase in the number of impending drugs in pipeline.